Document Detail


FDDNP binding using MR derived cortical surface maps.
MedLine Citation:
PMID:  19703569     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To assess quantitatively the cortical pattern profile of regional FDDNP binding to beta-amyloid and neurofibrillary tangles on MR derived cortical maps, FDDNP PET images were corrected for movement and partial volume (PV), and optimized for kernel size.
METHODS: FDDNP DVR PET images from 23 subjects (7 with Alzheimer's disease (AD), 6 with mild cognitive impairment and 10 controls) were obtained from Logan analysis using cerebellum as reference. A hemispheric cortical surface model for each subject was extracted from the MRI. The same transformations were applied to the FDDNP DVR PET images to map them into the same space. The cortical map with PV correction was calculated as the ratio of the DVR cortical surface and that of the simulated map, created from the mask derived from MRI and smoothed to the PET resolution. Discriminant analysis was used to order the FDDNP DVR cortical surfaces based on subjects' disease state. Linear regression was used to assess the rate of change of DVR vs. MMSE for each hemispheric cortical surface point.
RESULTS: The FDDNP DVR cortical surface corrected for movement and PV had less hemispheric asymmetry. Optimal kernel size was determined to be 9 mm. The corrected cortical surface map of FDDNP DVR showed clear spatial pattern that was consistent with the known pathological progression of AD.
CONCLUSION: Correcting for movement, PV as well as optimizing kernel size provide sensitive statistical analysis of FDDNP distribution which confirms in the living brain known pathology patterns earlier observed with cognitive decline with brain specimens.
Authors:
H D Protas; S-C Huang; V Kepe; K Hayashi; A Klunder; M N Braskie; L Ercoli; S Bookheimer; P M Thompson; G W Small; J R Barrio
Related Documents :
18632739 - The cortical signature of alzheimer's disease: regionally specific cortical thinning re...
15531019 - Correlation of mini-mental-state-examination (mmse), syndrom-kurztest (skt) and clock t...
16971629 - Mr imaging anatomy in neurodegeneration: a robust volumetric parcellation method of the...
17036339 - In vivo measurement of plaque burden in a mouse model of alzheimer's disease.
8981319 - Pure progressive clumsiness due to parietal atrophy in a young adult.
16990669 - Quantitative mr imaging in alzheimer disease.
16269369 - Musculoskeletal imaging with computed tomography and magnetic resonance imaging: when i...
3348149 - Three-dimensional canine renovascular structure and circulation visualized in situ with...
15302759 - Functional assessment of pulmonary vein stenosis using radionuclide ventilation/perfusi...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2009-08-22
Journal Detail:
Title:  NeuroImage     Volume:  49     ISSN:  1095-9572     ISO Abbreviation:  Neuroimage     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2009-10-20     Completed Date:  2010-01-04     Revised Date:  2011-09-26    
Medline Journal Info:
Nlm Unique ID:  9215515     Medline TA:  Neuroimage     Country:  United States    
Other Details:
Languages:  eng     Pagination:  240-8     Citation Subset:  IM    
Affiliation:
Department of Biomathematics, David Geffen School of Medicine at UCLA, University of California-Los Angeles, 10833 Le Conte Ave., Los Angeles, CA 90095, USA. hprotas@ucla.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Alzheimer Disease / pathology,  psychology
Brain Mapping
Cerebral Cortex / anatomy & histology*,  pathology,  radionuclide imaging*
Cognition Disorders / pathology,  psychology
Disease Progression
Female
Humans
Image Processing, Computer-Assisted
Magnetic Resonance Imaging / methods*
Male
Movement / physiology
Neuropsychological Tests
Nitriles / diagnostic use*,  pharmacokinetics*
Positron-Emission Tomography / methods*
Radiopharmaceuticals / diagnostic use*,  pharmacokinetics*
Regression Analysis
Grant Support
ID/Acronym/Agency:
AG10123/AG/NIA NIH HHS; AG13308/AG/NIA NIH HHS; M01 RR000865-310711/RR/NCRR NIH HHS; M01-RR00865/RR/NCRR NIH HHS; MH/AG58156/AG/NIA NIH HHS; MH52453/MH/NIMH NIH HHS; P01 AG025831-05/AG/NIA NIH HHS; P01-AG025831/AG/NIA NIH HHS; P30 AG010123-03/AG/NIA NIH HHS; P50 AG 16570/AG/NIA NIH HHS; P50 AG016570-109002/AG/NIA NIH HHS; R01 AG013308-10/AG/NIA NIH HHS; R01 MH052453-05/MH/NIMH NIH HHS; R01 MH058156-05/MH/NIMH NIH HHS
Chemical
Reg. No./Substance:
0/2-(1-(6-((2-fluoroethyl)(methyl)amino)-2-naphthyl)ethylidene)malononitrile; 0/Nitriles; 0/Radiopharmaceuticals
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Addiction related alteration in resting-state brain connectivity.
Next Document:  Cingulate activity and fronto-temporal connectivity in people with prodromal signs of psychosis.